GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma

BACKGROUND: Neuroblastoma is the most common extracranial solid tumor of childhood. Patients with high-risk disease undergo extremely aggressive therapy and nonetheless have cure rates below 50%. Treatment with the ch14.18 monoclonal antibody (dinutuximab beta), directed against the GD2 disialogangl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zirngibl, Felix, Ivasko, Sara M, Grunewald, Laura, Klaus, Anika, Schwiebert, Silke, Ruf, Peter, Lindhofer, Horst, Astrahantseff, Kathy, Andersch, Lena, Schulte, Johannes H, Lode, Holger N, Eggert, Angelika, Anders, Kathleen, Hundsdoerfer, Patrick, Künkele, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292814/
https://www.ncbi.nlm.nih.gov/pubmed/34285106
http://dx.doi.org/10.1136/jitc-2021-002923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292814/
https://www.ncbi.nlm.nih.gov/pubmed/34285106
http://dx.doi.org/10.1136/jitc-2021-002923

Ejemplares similares